Most Read Articles
6 days ago
The choice between nonvitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) for stroke prevention appears to be complex and largely heterogenous across different, countries, a new study has found.
Yesterday
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, Yesterday
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, 2 days ago
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.

Elevated maternal osteocalcin during early pregnancy ups risk of low birthweight

08 Oct 2018

Elevated levels of maternal osteocalcin during the first and second trimesters of pregnancy may increase the risk of having low birthweight (LBW) infants, a recent study has found.

Researchers performed a nested case-control study of 230 mothers (mean age 28.0±5.0 years) with LBW babies and 382 control pregnant mothers (mean age 28.1±4.7 years). Participants were matched for infant gender, maternal age and gestational age at blood sampling. Binary logistic regression models were used to estimate the relationship between maternal serum osteocalcin and 25-hydroxyvitamin D (25(OH)D) and LBW.

Relative to women with first trimester maternal osteocalcin 11.32 ng/mL, those with elevated levels were significantly more likely to give birth to LBW babies (20 vs 40; adjusted odds ratio [OR], 2.29; 95 percent CI, 1.11–4.72; p=0.025).

No such effect was documented for maternal 25(OH)D. There were 25 LBW infants in those with serum concentrations 64.82 nmol/L, which was not significantly different than in those with high measured levels (n=35; adjusted OR, 1.39; 0.72–2.67; p=0.325).

During the second trimester, the effect of osteocalcin remained significant (adjusted OR, 1.59; 1.03–2.45; p=0.036) while serum 25(OH)D continued to be unrelated to LBW risk (adjusted OR, 1.06; 0.69–1.62; p=0.790).

By the third trimester, the relationship between LBW risk and osteocalcin was attenuated (adjusted OR, 1.05; 0.40–2.80; p=0.919).

That osteocalcin acts as a hormone that improves glucose uptake by the foetus may explain the present findings, though further studies are required to conclusively identify the underlying mechanisms, said researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
The choice between nonvitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) for stroke prevention appears to be complex and largely heterogenous across different, countries, a new study has found.
Yesterday
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, Yesterday
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, 2 days ago
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.